Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction
Background ST-segment-elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin-1 blockade with anakinra significantly reduced the area under the curve for hsCRP (high sensitivity C-reactive protein) levels during the first 14 days in patients with ST-segment-elevation myocardial infarction (VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]). Methods and Results We conducted a randomized, placebo-controlled, double-blind, clinical trial in 99 patients with ST-segment-elevation myocardial infarction in which patients were assigned to 2 weeks treatment with anakinra once daily (N=33), anakinra twice daily (N=31), or placebo (N=35). hsCRP area under the curve was significantly lower in patients receiving anakinra versus placebo (median, 67 [interquartile range, 39-120] versus 214 [interquartile range, 131-394] mg·day/L; P<0.001), without significant differences between the anakinra arms. No significant differences were found between anakinra and placebo groups in the interval changes in left ventricular end-systolic volume (median, 1.4 [interquartile range, -9.8 to 9.8] versus -3.9 [interquartile range, -15.4 to 1.4] mL; P=0.21) or left ventricular ejection fraction (median, 3.9% [interquartile range, -1.6% to 10.2%] versus 2.7% [interquartile range, -1.8% to 9.3%]; P=0.61) at 12 months. The incidence of death or new-onset heart failure or of death and hospitalization for heart failure was significantly lower with anakinra versus placebo (9.4% versus 25.7% [P=0.046] and 0% versus 11.4% [P=0.011], respectively), without difference between the anakinra arms. The incidence of serious infection was not different between anakinra and placebo groups (14% versus 14%; P=0.98). Injection site reactions occurred more frequently in patients receiving anakinra (22%) versus placebo (3%; P=0.016). Conclusions In patients presenting with ST-segment-elevation myocardial infarction, interleukin-1 blockade with anakinra significantly reduces the systemic inflammatory response compared with placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01950299.
| Errataetall: |
CommentIn: J Cardiovasc Pharmacol. 2022 Jun 01;79(6):769-771. - PMID 35289771 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of the American Heart Association - 9(2020), 5 vom: 03. März, Seite e014941 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbate, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2021 Date Revised 30.08.2022 published: Print-Electronic ClinicalTrials.gov: NCT01950299 CommentIn: J Cardiovasc Pharmacol. 2022 Jun 01;79(6):769-771. - PMID 35289771 Citation Status MEDLINE |
|---|
| doi: |
10.1161/JAHA.119.014941 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307137112 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307137112 | ||
| 003 | DE-627 | ||
| 005 | 20231225124910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/JAHA.119.014941 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM307137112 | ||
| 035 | |a (NLM)32122219 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2021 | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01950299 | ||
| 500 | |a CommentIn: J Cardiovasc Pharmacol. 2022 Jun 01;79(6):769-771. - PMID 35289771 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background ST-segment-elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin-1 blockade with anakinra significantly reduced the area under the curve for hsCRP (high sensitivity C-reactive protein) levels during the first 14 days in patients with ST-segment-elevation myocardial infarction (VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]). Methods and Results We conducted a randomized, placebo-controlled, double-blind, clinical trial in 99 patients with ST-segment-elevation myocardial infarction in which patients were assigned to 2 weeks treatment with anakinra once daily (N=33), anakinra twice daily (N=31), or placebo (N=35). hsCRP area under the curve was significantly lower in patients receiving anakinra versus placebo (median, 67 [interquartile range, 39-120] versus 214 [interquartile range, 131-394] mg·day/L; P<0.001), without significant differences between the anakinra arms. No significant differences were found between anakinra and placebo groups in the interval changes in left ventricular end-systolic volume (median, 1.4 [interquartile range, -9.8 to 9.8] versus -3.9 [interquartile range, -15.4 to 1.4] mL; P=0.21) or left ventricular ejection fraction (median, 3.9% [interquartile range, -1.6% to 10.2%] versus 2.7% [interquartile range, -1.8% to 9.3%]; P=0.61) at 12 months. The incidence of death or new-onset heart failure or of death and hospitalization for heart failure was significantly lower with anakinra versus placebo (9.4% versus 25.7% [P=0.046] and 0% versus 11.4% [P=0.011], respectively), without difference between the anakinra arms. The incidence of serious infection was not different between anakinra and placebo groups (14% versus 14%; P=0.98). Injection site reactions occurred more frequently in patients receiving anakinra (22%) versus placebo (3%; P=0.016). Conclusions In patients presenting with ST-segment-elevation myocardial infarction, interleukin-1 blockade with anakinra significantly reduces the systemic inflammatory response compared with placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01950299 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a ST‐segment–elevation myocardial infarction | |
| 650 | 4 | |a acute myocardial infarction | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a interleukin‐1 | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Trankle, Cory R |e verfasserin |4 aut | |
| 700 | 1 | |a Buckley, Leo F |e verfasserin |4 aut | |
| 700 | 1 | |a Lipinski, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Appleton, Darryn |e verfasserin |4 aut | |
| 700 | 1 | |a Kadariya, Dinesh |e verfasserin |4 aut | |
| 700 | 1 | |a Canada, Justin M |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Charlotte S |e verfasserin |4 aut | |
| 700 | 1 | |a Abouzaki, Nayef |e verfasserin |4 aut | |
| 700 | 1 | |a Melchior, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Christopher, Sanah |e verfasserin |4 aut | |
| 700 | 1 | |a Turlington, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, George |e verfasserin |4 aut | |
| 700 | 1 | |a Garnett, James |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Markley, Roshanak |e verfasserin |4 aut | |
| 700 | 1 | |a Wohlford, George F |e verfasserin |4 aut | |
| 700 | 1 | |a Puckett, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Medina de Chazal, Horacio |e verfasserin |4 aut | |
| 700 | 1 | |a Chiabrando, Juan G |e verfasserin |4 aut | |
| 700 | 1 | |a Bressi, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Del Buono, Marco Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Schatz, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Vo, Chau |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
| 700 | 1 | |a Biondi-Zoccai, Giuseppe G |e verfasserin |4 aut | |
| 700 | 1 | |a Kontos, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Heart Association |d 2012 |g 9(2020), 5 vom: 03. März, Seite e014941 |w (DE-627)NLM222412712 |x 2047-9980 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:5 |g day:03 |g month:03 |g pages:e014941 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/JAHA.119.014941 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 5 |b 03 |c 03 |h e014941 | ||